Septerna Enters Major Collaboration with Novo Nordisk

Septerna, Inc. ( (SEPN) ) has provided an update.

On May 13, 2025, Septerna, Inc. and Novo Nordisk entered into a global collaboration and license agreement to develop oral small molecule therapies for metabolic-related diseases. This partnership will leverage Septerna’s Native Complex Platform™ to target multiple GPCRs, including GLP-1, GIP, and glucagon receptors. The agreement could potentially bring Septerna over $2.2 billion in payments, with Novo Nordisk covering all research and development expenses. This collaboration is expected to enhance Septerna’s industry positioning by providing significant resources to advance its GPCR-targeted programs.

The most recent analyst rating on (SEPN) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Septerna, Inc. stock, see the SEPN Stock Forecast page.

Spark’s Take on SEPN Stock

According to Spark, TipRanks’ AI Analyst, SEPN is a Neutral.

Septerna, Inc. faces significant challenges including operational inefficiencies, cash flow constraints, and weak technical indicators. The discontinuation of a key program adds pressure despite strategic realignment efforts. Lack of valuation metrics further complicates assessment. Improvement in operational efficiency and successful strategic shifts are crucial for enhancing stock performance.

To see Spark’s full report on SEPN stock, click here.

More about Septerna, Inc.

Septerna, Inc. is a biotechnology company focused on pioneering GPCR drug discovery using its proprietary Native Complex Platform™. The company aims to develop oral small molecule therapies for various therapeutic areas, including endocrinology, immunology, inflammation, and metabolic diseases.

Average Trading Volume: 511,574

Technical Sentiment Signal: Strong Sell

Current Market Cap: $310.7M

See more insights into SEPN stock on TipRanks’ Stock Analysis page.